| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/29/2002 | WO2002066427A2 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof |
| 08/29/2002 | WO2002066426A2 Fluoro oxindole derivatives as modulators of kcnq potassium channels |
| 08/29/2002 | WO2002066422A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 08/29/2002 | WO2002066420A2 Tryptase inhibitors |
| 08/29/2002 | WO2002066418A2 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor |
| 08/29/2002 | WO2002066078A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066077A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066075A2 Biotin-derivatives and their conjugates with chelating agents |
| 08/29/2002 | WO2002066072A1 Methods for the treatment and diagnosis of prostate cancer based on p75ntr tumor |
| 08/29/2002 | WO2002066070A1 Pharmaceutical compositions containing decoy and method of using the same |
| 08/29/2002 | WO2002066065A1 Calcium supplementation to reduce prostate cancer risk |
| 08/29/2002 | WO2002066061A1 Active oxygen generator containing photosensitizer for ultrasonic therapy |
| 08/29/2002 | WO2002066050A1 Casoase 3 inhibitors |
| 08/29/2002 | WO2002066048A1 Crystal modification of a cyclic depsipeptide having improved strength |
| 08/29/2002 | WO2002066047A1 Use of $g(g)-gt inhibitors for the treatment of degenerative diseases |
| 08/29/2002 | WO2002066040A2 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 08/29/2002 | WO2002066038A1 Treatment of refractory tumors using epothilone derivatives |
| 08/29/2002 | WO2002066037A2 Antiviral method of use |
| 08/29/2002 | WO2002066036A1 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| 08/29/2002 | WO2002066035A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/29/2002 | WO2002066034A1 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 08/29/2002 | WO2002066033A1 Epothilone derivatives for the treatment of refractory tumors |
| 08/29/2002 | WO2002066032A1 Treatment of schizophrenia |
| 08/29/2002 | WO2002066031A1 Utilization of buprenorphine in urinary incontinence therapy |
| 08/29/2002 | WO2002066030A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | WO2002066029A2 Antiprotozoal methods, compositions and feedstuffs |
| 08/29/2002 | WO2002066028A2 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids |
| 08/29/2002 | WO2002066027A1 Agent for inhibiting tumour cells |
| 08/29/2002 | WO2002066026A2 Tramadol-based medicament |
| 08/29/2002 | WO2002066025A2 Combination of active ingredients consisting of the racemate of tramadol and of (+)-o-desmethyltramadol |
| 08/29/2002 | WO2002066024A1 Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria |
| 08/29/2002 | WO2002066023A1 Use of a cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications |
| 08/29/2002 | WO2002066022A1 Retinoid hepatitis therapy |
| 08/29/2002 | WO2002066021A2 Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis |
| 08/29/2002 | WO2002066020A2 Modulation of gsk-3beta activity and its different uses |
| 08/29/2002 | WO2002066019A2 Cancer treatment |
| 08/29/2002 | WO2002066018A2 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 08/29/2002 | WO2002066017A1 Liothyronine sodium and levothyroxine sodium combination |
| 08/29/2002 | WO2002066016A2 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine |
| 08/29/2002 | WO2002066015A1 Use of polyalkylamine polymers in controlled release devices |
| 08/29/2002 | WO2002066012A2 Amphoteric liposomes and the use thereof |
| 08/29/2002 | WO2002066011A1 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066010A1 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066009A1 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066008A1 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066006A1 Sustained-release suspension of ceftiofur hydrochloride |
| 08/29/2002 | WO2002066002A2 Pharmaceutical formulation |
| 08/29/2002 | WO2002066001A1 Topical solution containing a chromane or chromene derivative |
| 08/29/2002 | WO2002066000A2 Novel cosmetic slimming compositions containing boldine |
| 08/29/2002 | WO2002065993A2 Use of aryl nitrone compounds in methods for treating neuropathic pain |
| 08/29/2002 | WO2002065991A2 Divalproex sodium tablets |
| 08/29/2002 | WO2002065989A2 Aminoglycoside treatment for lysosomal storage diseases |
| 08/29/2002 | WO2002065988A2 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 08/29/2002 | WO2002065986A2 Transporters comprising spaced arginine moieties |
| 08/29/2002 | WO2002065981A2 Chemotherapeutic composition using calcium phosphate paste |
| 08/29/2002 | WO2002065979A2 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 08/29/2002 | WO2002065977A2 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| 08/29/2002 | WO2002065941A2 Method of controlling body temperature |
| 08/29/2002 | WO2002065859A1 Emulsions and aqueous dispersions of phytosterols |
| 08/29/2002 | WO2002065834A2 Novel formulations of carvedilol |
| 08/29/2002 | WO2002047668A3 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 08/29/2002 | WO2002045753A3 Oral extended release formulation of gepirone |
| 08/29/2002 | WO2002042273A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002041925B1 Sterilisation of pharmaceuticals |
| 08/29/2002 | WO2002040466A3 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for treating of nervous systems disorders |
| 08/29/2002 | WO2002039991A3 Prevention of development of dyskinesias |
| 08/29/2002 | WO2002037937A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002034233A3 Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing |
| 08/29/2002 | WO2002030930A3 Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 08/29/2002 | WO2002028867A3 Ethers of 7-desmethylrapamycin for use in immunosuppression |
| 08/29/2002 | WO2002028858A3 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 08/29/2002 | WO2002028346A3 Association of the cb1 receptor antagonist and sibutramin, for treating obesity |
| 08/29/2002 | WO2002022621A3 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 08/29/2002 | WO2002022620A3 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002018383A3 Aza heterocyclic derivatives and their therapeutic use |
| 08/29/2002 | WO2002018324A3 Immunoregulatory compounds, derivatives thereof and their use |
| 08/29/2002 | WO2002015894A3 Use of vitamin d derivatives as bone resorption inhibitors |
| 08/29/2002 | WO2002010403A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 08/29/2002 | WO2002008256A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 08/29/2002 | WO2002008241A3 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 08/29/2002 | WO2002007700A3 Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates |
| 08/29/2002 | WO2002007685A3 Method of regulating hair growth using metal complexes of oxidized carbohydrates |
| 08/29/2002 | WO2002005856A3 Acyclic isoprenoid ether derivatives as chemotherapuetics |
| 08/29/2002 | WO2002003988A3 Use of substituted indole compounds for treating neuropeptide y-related conditions |
| 08/29/2002 | WO2002002525A3 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 08/29/2002 | WO2002002506A3 Compounds to treat alzheimer's disease |
| 08/29/2002 | WO2002000641A3 Spla2 inhibitors |
| 08/29/2002 | WO2002000619A3 Alkyl ether modified polycyclic compounds having a terminal phenol as cell protecting agents |
| 08/29/2002 | WO2002000227A3 Use of lanthanum compounds for the treatment of bone diseases |
| 08/29/2002 | WO2001097805A3 Solid valsartan pharmaceutical compositions |
| 08/29/2002 | WO2001091745A3 Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions |
| 08/29/2002 | WO2001087288A8 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists |
| 08/29/2002 | WO2001085944A3 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 08/29/2002 | WO2001085154A3 Method of treating immune pathologies with low dose estrogen |
| 08/29/2002 | WO2001085093A3 Compounds and methods for modulating cerebral amyloid angiopathy |
| 08/29/2002 | WO2001085092A3 Antidiarrheal cannabinoid cb-1 receptor antagonist |
| 08/29/2002 | WO2001079284A3 Therapeutic compounds and methods for formulating v3, a versican isoform |
| 08/29/2002 | WO2001070206A3 Combination of lecithin with ascorbic acid |
| 08/29/2002 | WO2001068053A3 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |